한빛사논문
- 조회596
Donghee Kim, MD, PhD1, Omar Alshuwaykh, MD1, Brittany B. Dennis, MD, PhD2, George Cholankeril, MD, MSECR3,4, Aijaz Ahmed, MD1
1Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, United States
2Department of Medicine, McMaster University, Hamilton, ON, L8S 4L8, Canada
3Liver Center, Division of Abdominal Transplantation, Michael E DeBakey Department of General Surgery, Baylor College of Medicine, Houston, Texas, United States
4Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, United States
Corresponding Author: Donghee Kim, MD, PhD
Abstract
Background Aims
During the global coronavirus disease-2019 (COVID-19) pandemic, patients with pre-existing chronic liver disease may represent a vulnerable population. We studied the etiology-based temporal trends in mortality of chronic liver disease and the underlying cause of death in the United States before and during the COVID-19 pandemic.
Methods
Population-based analyses were performed on US national mortality records (2017- 2020). Temporal trends in quarterly age-standardized mortality were obtained by joinpoint analysis with estimates of quarterly percentage change (QPC).
Results
Quarterly age-standardized all-cause mortality due to alcohol-related liver disease (ALD) initially increased at a quarterly rate of 1.1% before the COVID-19 pandemic, followed by a sharp increase during the COVID-19 pandemic at a quarterly rate of 11.2%. Likewise, steady increase in mortality of nonalcoholic fatty liver disease (NAFLD) before the COVID-19 pandemic (QPC: 1.9%) accelerated during the COVID-19 pandemic (QPC: 6.6%). While ALD-related mortality increased steeply compared to viral hepatitis-related mortality during the COVID-19 pandemic, the proportion of mortality due to COVID-19 among individuals with ALD was the lowest at 2.5%; more than 50% lower than viral hepatitis. The significant decline in all-cause mortality due to viral hepatitis before the COVID-19 pandemic plateaued during the COVID-19 pandemic due to increase in COVID-19-related mortality in individuals with viral hepatitis. Mortality due to cirrhosis increased markedly during the COVID-19 pandemic, mainly attributable to ALD.
Conclusion
All-cause mortality for ALD and NAFLD rapidly accelerated during the COVID-19 pandemic compared to the pre-COVID-19 era. There has been a significant decline in viral hepatitis; however, a significant increase in COVID-related death in this population.
논문정보
- Research article
- 2022년 07월 (BRIC 등록일 2022-07-15)
- 국외 연구진
- 의약학 > 응용의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
